Elekta (OTCMKTS:EKTAY) Shares Gap Down – What’s Next?

Shares of Elekta AB (OTCMKTS:EKTAYGet Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $5.5599, but opened at $5.00. Elekta shares last traded at $5.00, with a volume of 2,722 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research cut shares of Elekta from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 2nd. Two analysts have rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Get Our Latest Report on Elekta

Elekta Stock Performance

The company’s fifty day moving average is $5.91 and its 200 day moving average is $6.07. The company has a market capitalization of $1.85 billion, a P/E ratio of -31.41 and a beta of 1.00. The company has a current ratio of 0.95, a quick ratio of 0.73 and a debt-to-equity ratio of 0.56.

Elekta (OTCMKTS:EKTAYGet Free Report) last issued its earnings results on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 10.67%. The business had revenue of $521.00 million for the quarter. As a group, equities analysts anticipate that Elekta AB will post 0.43 earnings per share for the current year.

Elekta Company Profile

(Get Free Report)

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

Featured Articles

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.